GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » ROE %

DYAI (Dyadic International) ROE % : -24.68% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dyadic International ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Dyadic International's annualized net income for the quarter that ended in Sep. 2024 was $-0.81 Mil. Dyadic International's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $3.29 Mil. Therefore, Dyadic International's annualized ROE % for the quarter that ended in Sep. 2024 was -24.68%.

The historical rank and industry rank for Dyadic International's ROE % or its related term are showing as below:

DYAI' s ROE % Range Over the Past 10 Years
Min: -3947.19   Med: -25.11   Max: 183.94
Current: -128.51

During the past 13 years, Dyadic International's highest ROE % was 183.94%. The lowest was -3,947.19%. And the median was -25.11%.

DYAI's ROE % is ranked worse than
80.23% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs DYAI: -128.51

Dyadic International ROE % Historical Data

The historical data trend for Dyadic International's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International ROE % Chart

Dyadic International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.22 -29.00 -55.81 -66.05 -80.10

Dyadic International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.61 -122.49 -154.69 -212.91 -24.68

Competitive Comparison of Dyadic International's ROE %

For the Biotechnology subindustry, Dyadic International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyadic International's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's ROE % distribution charts can be found below:

* The bar in red indicates where Dyadic International's ROE % falls into.



Dyadic International ROE % Calculation

Dyadic International's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-6.795/( (11.088+5.879)/ 2 )
=-6.795/8.4835
=-80.10 %

Dyadic International's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-0.812/( (3.168+3.412)/ 2 )
=-0.812/3.29
=-24.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Dyadic International  (NAS:DYAI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-0.812/3.29
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.812 / 7.832)*(7.832 / 10.718)*(10.718 / 3.29)
=Net Margin %*Asset Turnover*Equity Multiplier
=-10.37 %*0.7307*3.2578
=ROA %*Equity Multiplier
=-7.58 %*3.2578
=-24.68 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-0.812/3.29
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.812 / -0.812) * (-0.812 / -0.788) * (-0.788 / 7.832) * (7.832 / 10.718) * (10.718 / 3.29)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0305 * -10.06 % * 0.7307 * 3.2578
=-24.68 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Dyadic International ROE % Related Terms

Thank you for viewing the detailed overview of Dyadic International's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyadic International Business Description

Traded in Other Exchanges
N/A
Address
1044 North U.S. Highway One, Suite 201, Jupiter, FL, USA, 33477
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Executives
Ronen Tchelet officer: VP of Research and Bus. Dvlpmt 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb director, 10 percent owner, officer: President, CEO & Chairman C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton officer: Chief Business Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996 10 percent owner C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones officer: Managing Dir of BD & Licensing 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst director 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland director C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson officer: Chief Financial Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok director KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose director 4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson 10 percent owner 1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020